Pharmstandard International S.A. maintained its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 982,270 shares of the company’s stock at the close of the 2nd quarter. Protagonist Therapeutics accounts for about 38.5% of Pharmstandard International S.A.’s investment portfolio, making the stock its largest holding. Pharmstandard International S.A. owned approximately 5.81% of Protagonist Therapeutics worth $11,109,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Senzar Asset Management LLC acquired a new stake in shares of Protagonist Therapeutics in the second quarter valued at approximately $3,094,000. Teachers Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 9,461 shares of the company’s stock valued at $208,000 after purchasing an additional 1,424 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Protagonist Therapeutics by 15.1% in the first quarter. Bank of New York Mellon Corp now owns 26,148 shares of the company’s stock valued at $335,000 after purchasing an additional 3,433 shares during the last quarter. FMR LLC increased its holdings in shares of Protagonist Therapeutics by 0.4% in the first quarter. FMR LLC now owns 2,518,198 shares of the company’s stock valued at $32,258,000 after purchasing an additional 11,031 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Protagonist Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after purchasing an additional 11,881 shares during the last quarter. 48.04% of the stock is owned by hedge funds and other institutional investors.

In related news, insider David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $15.00, for a total transaction of $52,500.00. Following the completion of the transaction, the insider now directly owns 5,500 shares in the company, valued at approximately $82,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Richard S. Shames sold 3,687 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $14.31, for a total value of $52,760.97. The disclosure for this sale can be found here. Insiders have sold a total of 12,199 shares of company stock valued at $175,345 over the last 90 days.

Several equities research analysts recently commented on PTGX shares. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 18th. BTIG Research started coverage on Protagonist Therapeutics in a report on Friday, July 21st. They issued a “buy” rating and a $36.00 price target for the company. Finally, ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th.

TRADEMARK VIOLATION NOTICE: “Pharmstandard International S.A. Has $11,109,000 Stake in Protagonist Therapeutics, Inc. (PTGX)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/07/pharmstandard-international-s-a-has-11109000-stake-in-protagonist-therapeutics-inc-ptgx.html.

Protagonist Therapeutics, Inc. (PTGX) traded down 2.39% during midday trading on Friday, hitting $18.76. The company had a trading volume of 17,683 shares. The stock’s market cap is $317.08 million. Protagonist Therapeutics, Inc. has a 52-week low of $8.00 and a 52-week high of $26.36. The stock’s 50-day moving average price is $15.94 and its 200-day moving average price is $12.55.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.70).

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.